A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy

Unresectable Metastatic Colorectal Cancer Clinical Trial

Official title:
A Single Center, Open-labeled, Single Arm Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy

Status Recruiting

Clinical Trial Summary

This is a single center, open-labeled, single arm phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients unsuitable for intravenous chemotherapy.

Clinical Trial Description

Fruquintinib is an oral small molecule inhibitor of VEGFR1/2/3, this phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients of elderly or those unsuitable for intravenous chemotherapy. ;

Study Design

Related Conditions & MeSH terms

Colorectal Neoplasms
Unresectable Metastatic Colorectal Cancer

Clinical Trial Details

NCT number	NCT04866108
Study type	Interventional
Source	Beijing Friendship Hospital
Contact	Zhigang Bai
Phone	+86-010-63138712
Email	baizhigang@ccmu.edu.cn
Status	Recruiting
Phase	Phase 2
Start date	December 8, 2021
Completion date	June 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05068206` - A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx	Phase 2
Not yet recruiting	`NCT04131803` - Probiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Cancer	N/A
Recruiting	`NCT03692429` - alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells	Phase 1
Recruiting	`NCT04991948` - Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer	Phase 1
Recruiting	`NCT06107413` - Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab	Phase 2
Completed	`NCT01802684` - OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT04160416` - mXELOXIRI Combined With Molecular Targeted Drug in mCRC	Phase 2